Corcept Q1 2026 Demand Outlook and Future Sales Potential

Q1 2026 demand outlook for Corcept’s medications and potential sales impact

Demand outlook: strengthening and building through early 2026

In Corcept’s Q1 2026 earnings call, management stated that demand for its medications continues to increase and that the quarter ended with a record number of new prescriptions and a record number of prescribers, which “translated to an all-time high for the number of patients receiving our medications.” ¹ They also said they set a record for new patient starts in March and again in April. ¹

Importantly, management emphasized that demand momentum is not yet fully reflected in revenue, and gave three specific reasons the timing of demand translates imperfectly into Q1 sales: (1) first-quarter revenue can dip due to annual payer reauthorization procedures that interrupt patient coverage for a month or 2, partially offset by free drug bridging (but with revenue still suffering); ¹ (2) new patients contribute less revenue initially because payer coverage and titration to an optimum dose take time; ¹ and (3) the specialty pharmacy vendor (Curant) was transitioning thousands of patients and onboarding new prescriptions, and while this supported volume, there remained work to clear a prior authorization backlog accumulated during transitions—management characterized this as “painstaking work” that should show dividends in later periods. ¹

Bottom line on Q1 2026 demand: the record new prescription/patient-start data indicates ongoing, accelerating underlying demand heading into and throughout Q1 2026, but reported sales in that quarter are temporarily muted by payer/coverage timing and vendor/prior-auth execution. ¹

---

How this demand could impact sales (near-term mechanics)

Management explicitly laid out how Q1 demand should flow into future revenue:

1. Coverage disruptions at year-start likely depressed Q1 revenue despite demand strength
   Corcept noted that insurance reauthorization procedures at the start of each year can interrupt patient coverage for 1–2 months, creating a revenue dip even though patients are supported with free drug. ¹
   Implication: even with rising demand (record starts/prescriptions), Q1 revenue may understate the demand trend.

2. Revenue ramp for newly added patients should increase in subsequent quarters
   Corcept said new patients added rapidly this quarter generate less revenue when they start than they will later after payer coverage is secured and titration occurs. ¹
   Implication: later Q2/Q3 revenue should rise as those patients move to full coverage and higher effective dosing.

3. Prior authorization backlog clearance should show up over coming months
   Corcept attributed part of the timing gap to the remaining effort to clear the prior authorization backlog from the pharmacy transition. ¹
   Implication: sales should benefit as authorizations are processed and patients remain on therapy consistently.

Additionally, management supported execution and scalability: they praised the specialty pharmacy’s onboarding and servicing of both transferred and new prescriptions, noting an all-time high at the time. ² They also acknowledged that at some point volume may exceed what a single pharmacy can handle, and said the plan is to expand the network, with additional support expected in the fourth quarter of 2026. ²
Implication: this signals that demand growth is likely to continue, and the company appears to be planning operational capacity to sustain it—though the specific Q1 2026 sales uplift would primarily depend on payer authorization timing and patient ramp effects already described. ²

---

Why management expects demand to accelerate further (and what that means for sales)

Corcept linked the demand trajectory to clinical evidence adoption. They stated physicians have begun responding to the CATALYST and MOMENTUM findings, but that “a change of this magnitude takes some time” to be absorbed; as practices adapt, screening and treatment should increase, and therefore the number of patients receiving their medications will increase. ³ They further stated they expect demand to increase substantially as physicians adapt their practices to the “landmark findings” of those trials. ¹

They also reiterated a growth expectation for the Cushing’s syndrome business—at least $2 billion in annual revenue by the end of the decade, and that growth should accelerate further when relacorilant is available. ³
Implication for Q1 2026: this supports the view that the current demand strength is not a one-off quarter, but part of a larger adoption curve that should support improving sales over time, even if Q1 is temporarily constrained by coverage and ramp effects. ³

---

Conclusion: Q1 2026 demand is strong; sales impact likely shows more in subsequent quarters

• Demand outlook in Q1 2026: Strong and improving, evidenced by record new prescriptions/prescribers, all-time high patients, and record new patient starts in March and April. ¹
• Potential impact on sales: Q1 revenue likely lags the demand trend because of payer reauthorization timing, lower early revenue from new starts before full coverage and titration, and a prior authorization backlog from pharmacy transitions. ¹
• Expected direction: As those timing frictions clear and patients ramp on treatment, the company implies that revenue benefits should appear over the coming months, consistent with the described “full impact” not being reflected yet in Q1. ¹

Overall, the excerpted management commentary supports a view that underlying demand is increasing in Q1 2026, but reported sales from that demand are partially deferred due to insurance coverage and ramp logistics rather than a weakening demand environment. ¹